Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 5/2016

01-10-2016 | Invited Review Article

Clinical features and treatment strategy for HPV-related oropharyngeal cancer

Author: Kenji Okami

Published in: International Journal of Clinical Oncology | Issue 5/2016

Login to get access

Abstract

Among head and neck squamous cell carcinoma (HNSCC), the incidence of oropharyngeal SCC (OPSCC) is increasing in contrast to carcinoma with origin in other subsites. Human papillomavirus (HPV) is now recognized as a significant risk factor of the carcinogenesis of OPSCC. The HPV-related OPSCC patients tend to be relatively young, less exposed to tobacco and alcohol, and have a relatively high socioeconomic status and education level, which is distinct from HPV-unrelated classical OPSCC. The neck metastases tend to be aggressive and cystic. The better response to treatment resulting in improved prognosis of HPV-related OPSCC led to reconsidering the clinical staging and treatment approaches. Clinical trials of treatment deintensification to reduce the acute and late toxicity without compromising efficacy have been conducted. This review of HPV-related OPSCC focuses on current and generally accepted facts regarding the biology, epidemiology, and therapeutic strategy of this new disease entity.
Literature
1.
Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: Globocan. Int J Cancer 127:2893–2917CrossRefPubMed
2.
van Monsjou HS, Balm AJ, van den Brekel MM et al (2010) Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol 46:780–785CrossRefPubMed
3.
Mignogna MD, Fedele S, Lo Russo L (2004) The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev 13:139–142CrossRefPubMed
4.
5.
Japan Society for Head and Neck Cancer Registry Committee (2015) Report of head and neck cancer registry of Japan Clinical statistics of registered patients, 2013. Jpn J Head Neck Cancer 41(suppl):1–14
6.
Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301CrossRefPubMedPubMedCentral
7.
Sturgis EM, Ang KK (2011) The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Cancer Netw 9:665–673
8.
Sturgis EM, Cinciripini PM (2007) Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer (Phila) 110:1429–1435CrossRef
9.
Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720CrossRefPubMed
10.
D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956CrossRefPubMed
11.
Chaturvedi AK, Engels EA, Anderson WF et al (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612–619CrossRefPubMed
12.
Dürst M, Gissmann L, Ikenberg H et al (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80:3812–3815CrossRefPubMedPubMedCentral
13.
zur Hausen H (2009) The search for infectious causes of human cancers: where and why. Virology 392:1–10CrossRefPubMed
14.
Stubenrauch F, Laimins LA (1999) Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol 9:379–386CrossRefPubMed
15.
Kreimer AR, Clifford GM, Boyle P et al (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467–475CrossRefPubMed
16.
Hama T, Tokumaru Y, Fujii M et al (2014) Prevalence of human papillomavirus in oropharyngeal cancer: a multicenter study in Japan. Oncology 87:173–182CrossRefPubMed
17.
Stanley MA, Pett MR, Coleman N (2007) HPV: from infection to cancer. Biochem Soc Trans 35:1456–1460CrossRefPubMed
18.
Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550–560CrossRefPubMed
19.
Jeon S, Lambert PF (1995) Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92:1654–1658CrossRefPubMedPubMedCentral
20.
Ragin CC, Reshmi SC, Gollin SM (2014) Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer 110:701–709CrossRef
21.
Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed
22.
Ndiaye C, Mena M, Alemany L et al (2014) HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 15:1319–1331CrossRefPubMed
23.
Allen CT, Lewis JS Jr, El–Mofty SK et al (2010) Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 120:1756–1772CrossRefPubMed
24.
25.
26.
27.
28.
29.
30.
31.
Klussmann JP, Gültekin E, Weissenborn SJ et al (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162:747–753CrossRefPubMedPubMedCentral
32.
Begum S, Cao D, Gillison M et al (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694–5699CrossRefPubMed
33.
Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269CrossRefPubMed
34.
Licitra L, Perrone F, Bossi P et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636CrossRefPubMed
35.
Shi W, Kato H, Perez-Ordonez B et al (2009) Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213–6221CrossRefPubMed
36.
Smeets SJ, Hesselink AT, Speel EJ et al (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472CrossRefPubMed
37.
Chaturvedi AK, Anderson WF, Lortet-Tieulent J et al (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31:4550–4559CrossRefPubMedPubMedCentral
38.
Upile NS, Shaw RJ, Jones TM et al (2014) Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related. Laryngoscope 124:2739–2744CrossRefPubMed
39.
Mineta H, Ogino T, Amano HM et al (1998) Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res 18:4765–4768PubMed
40.
Mizumachi T, Kano S, Sakashita T et al (2013) Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Int J Clin Oncol 18:824–828CrossRefPubMed
41.
Maruyama H, Yasui T, Ishikawa-Fujiwara T et al (2014) Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci 105:409–417CrossRefPubMedPubMedCentral
42.
Saito Y, Yoshida M, Ushiku T et al (2013) Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma. Cancer (Phila) 119:2005–2011CrossRef
43.
Gillison ML, Chaturvedi AK, Anderson WF et al (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33:3235–3242CrossRefPubMedPubMedCentral
44.
Elrefaey S, Massaro MA, Chiocca S et al (2014) HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital 34:299–309PubMedPubMedCentral
45.
de Martel C, Ferlay J, Franceschi S et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615CrossRefPubMed
46.
Urban D, Corry J, Rischin D (2014) What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer? Cancer 120:1462-1470
47.
Benard VB, Johnson CJ, Thompson TD et al (2008) Examining the association between socioeconomic status and potential human papillomavirus associated cancers. Cancer (Phila) 113:2910–2918CrossRef
48.
Markowitz LE, Sternberg M, Dunne EF et al (2009) Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. J Infect Dis 200:1059–1067CrossRefPubMed
49.
Darwich L, Canadas MP, Videla S et al (2014) Can Ruti HIV-HPV Team. Oral human papillomavirus type-specific infection in HIV-infected men: a prospective cohort study among men who have sex with men and heterosexual men. Clin Microbiol Infect 20:O585–O589CrossRefPubMed
50.
Beachler DC, D’Souza G, Sugar EA et al (2013) Natural history of anal vs. oral HPV infection in HIV-infected men and women. J Infect Dis 208:330–339CrossRefPubMedPubMedCentral
51.
Slaughter DP, Southwick HW, Smejkal W (1953) Cancer field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (Phila) 6:963–968
52.
Huang SH, Perez-Ordonez B, Liu FF et al (2012) Atypical clinical behaviour of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82:276–283CrossRefPubMed
53.
Goldenberg D, Begum S, Westra WH et al (2008) Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 30:898–903CrossRefPubMed
54.
Yasui T, Morii E, Yamamoto Y et al (2014) Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin. PLoS One 9:e95364CrossRefPubMedPubMedCentral
55.
McQuone SJ, Eisele DW, Lee DJ et al (1998) Occult tonsillar carcinoma in the unknown primary. Laryngoscope 108:1605–1610CrossRefPubMed
56.
Ebisumoto K, Okami K, Sakai A et al (2016) Successful detection of a minute tonsillar cancer lesion on transoral examination with narrow band imaging: a report of 2 cases. Head Neck 38:E2421–E2424CrossRefPubMed
57.
Koch WM, Batti N, Williams MF et al (2001) Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 124:331–333CrossRefPubMed
58.
Cianchetti M, Mancuso AA, Amdur RJ et al (2009) Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 119:2348–2354CrossRefPubMed
59.
Kobayashi K, Saito Y, Omura G et al (2014) Clinical features of human papilloma virus-related head and neck squamous cell carcinoma of an unknown primary site. ORL J Otorhinolaryngol Relat Spec 76:137–146CrossRefPubMed
60.
Begum S, Gillison ML, Ansari-Lari MA (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469–6475PubMed
61.
El-Mofty SK, Zhang MQ, Davila RM (2008) Histologic identification of human papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a reliable predictor of the site of an occult head and neck primary carcinoma. Head Neck Pathol 2:163–168CrossRefPubMedPubMedCentral
62.
Nakahara S, Yasui T, Takenaka Y et al (2014) Synchronous bilateral tonsillar carcinomas associated with human papillomavirus. Auris Nasus Larynx 41:109–112CrossRefPubMed
63.
Kothari P, Randhawa PS, Farrell R (2008) Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck. Br J Oral Maxillofac Surg 46:283–287CrossRefPubMed
64.
Rasband-Lindquist A, Shnayder Y, O’Neil M (2016) Synchronous bilateral tonsillar squamous cell carcinoma related to human papillomavirus: two case reports and a brief review of the literature. Ear Nose Throat J 95:E30–E34PubMed
65.
Waltonen JD, Ozer E, Hall NC et al (2009) Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup. Arch Otolaryngol Head Neck Surg 135:1024–1029CrossRefPubMed
66.
Marur S, D’Souza G, Westra WH et al (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789CrossRefPubMed
67.
Chung CH, Gillison ML (2009) Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15:6758–6762CrossRefPubMed
68.
Rischin D, Young RJ, Fisher R et al (2010) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142–4148CrossRefPubMedPubMedCentral
69.
Lassen P, Eriksen JG, Krogdahl A et al (2010) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomized DAHANCA 6&7 trial. Radiother Oncol 100:49–55CrossRef
70.
Posner M, Lorche J, Goloubeva O et al (2010) Survival and human papillomavirus in oropharynx cancer in TAX324: a subset analysis from an international phase III trial. Ann Oncol 22:1071–1077CrossRef
71.
O’Rorke MA, Ellison MV, Murray LJ et al (2012) Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 48:1191–1201CrossRefPubMed
72.
73.
Klussmann JP, Mooren JJ, Lehnen M et al (2009) Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 15:1779–1786CrossRefPubMed
74.
Lindel K, Beer KT, Laissue J et al (2001) Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer (Phila) 92:805–813CrossRef
75.
Vu HL, Sikora AG, Fu S et al (2010) HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 288:149–155CrossRefPubMed
76.
Gillison ML, Zhang Q, Jordan R et al (2012) Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102–2111CrossRefPubMedPubMedCentral
77.
Huang SH, Xu W, Waldron J et al (2015) Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 33:836–845CrossRefPubMed
78.
O’Sullivan B, Huang SH, Su J, et al. (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 26:S1470–S2045
79.
80.
Chera BS, Amdur RJ, Tepper J et al (2015) Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 93:976–985CrossRefPubMed
81.
82.
Morimoto A, Ueda Y, Egawa-Takata T et al (2015) Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination. Int J Clin Oncol 20:549–555CrossRefPubMed
83.
Hanley SJ, Yoshioka E, Ito Y et al (2015) HPV vaccination crisis in Japan. Lancet 385:2571PubMed
84.
Dornbusch HJ, Stiris T, Del Torso S et al (2015) Human papillomavirus vaccination crisis in Japan. J Paediatr Child Health 51:1146–1147CrossRefPubMed
85.
Isaranuwatchai W, Graham DM, Siu LL et al (2014) Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer? Expert Rev Pharmacoecon Outcomes Res 14(6):763–765CrossRefPubMed
86.
Kim JJ, Goldie SJ (2009) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339:b3884CrossRefPubMedPubMedCentral
87.
Elbasha EH, Dasbach EJ (2010) Impact of vaccinating boys and men against HPV in the United States. Vaccine 28:6858–6867CrossRefPubMed
88.
Graham DM, Isaranuwatchai W, Habbous S et al (2015) A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer (Phila) 121:1785–1792CrossRef
89.
Guo T, Eisele DW, Fakhry C (2016) The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer (Phila) doi: 10.​1002/​cncr.​29992. (epub ahead of print)
90.
Herrero R, Quint W, Hildesheim A et al (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 8:e68329CrossRefPubMedPubMedCentral
91.
Beachler DC, Kreimer AR, Schiffman M, et al; Costa Rica HPV Vaccine Trial (CVT) Group (2016) Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst 108:pii djv302
92.
Khwaja SS, Baker C, Haynes W, et al (2016) High E6 gene expression predicts for distant metastasis and poor survival in patients with HPV-positive oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys S03606(16)00240-6
93.
Vainshtein JM, Sector ME, Ibrahim M et al (2016) Matted nodes: high distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. Head Neck 38(suppl 1):E805–E814CrossRefPubMed
Metadata
Title
Clinical features and treatment strategy for HPV-related oropharyngeal cancer
Author
Kenji Okami
Publication date
01-10-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1009-6

Other articles of this Issue 5/2016

International Journal of Clinical Oncology 5/2016 Go to the issue

Original Article

Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy

Original Article

The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases

Invited Review Article

The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma

Letter to the Editor

Comment on Ueno et al.: Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan

Original Article

Preoperative biliary drainage-related inflammation is associated with shorter survival in biliary tract cancer patients

Original Article

Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with salvage surgery after concurrent chemoradiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits